… Prophylactic cranial irradiation (PCI) is considered standard of care in patients with
limited-stage small-cell lung cancer (SCLC) 1,2 and is still under debate in extensive disease. The …

… toxicity analysis before proceeding into phase III. We report here on the results from the
randomized phase II section of the trial, which triggered the decision to proceed into phase III. …

… We now report the results from a randomized phase III trial among patients with relatively …
4-week interval between cycles without blood progenitor cell or growth factor support (standard …

… in two randomized phase III studies in advanced NSCLC. … Lung cancer is the most common
cause of cancer death 1 and … in patients with non–small-cell lung cancer (NSCLC) appear to …

Purpose This phase II study evaluated the safety and efficacy of single-agent amrubicin
versus topotecan in patients with small-cell lung cancer (SCLC) sensitive to first-line platinum-…

… A randomized phase II trial of carboplatin (area under the curve [AUC], 6) and paclitaxel (…
conducted in 73 patients with advanced non–small-cell lung cancer (NSCLC), 7 a population in …

… In the present trial, we used a randomized phase II design in chemonaive patients with
locally advanced or metastatic NSCLC to simultaneously evaluate the activity of two regimens …

PURPOSE: This randomized trial was designed to determine whether paclitaxel plus carboplatin
(PC) offered a survival advantage over vinorelbine plus cisplatin (VC) for patients with …

… small-cell lung cancer and can lead to improved long-term survival, 3 has also been investigated
in the treatment of localized NSCLC. All these phase III … started a randomized phase III …

… safety concerns, the randomized phase was initiated. Patients were randomly assigned 2:1:…
The primary objectives of the randomized phase were to determine whether vandetanib 300 …